ライフサイエンスコーパス: antibiotics

1 tive barrier against the immune response and antibiotics.

2 ly occurs at environmental concentrations of antibiotics.

3 tion and permits evaluation of efficacies of antibiotics.

4 pecies as well as cellular stress induced by antibiotics.

5 septic shock warrant emergent broad-spectrum antibiotics.

6 ldren's care in addition to the provision of antibiotics.

7 rted allergies to both PCN and cephalosporin antibiotics.

8 species that contained AMR phenotypes for 29 antibiotics.

9 72.3% of episodes never required intravenous antibiotics.

10 to OM lipid asymmetry sensitize the cell to antibiotics.

11 f pathogens from the bactericidal effects of antibiotics.

12 mize clinical management and minimize use of antibiotics.

13 nd higher odds of earlier discontinuation of antibiotics.

14 eating an efficient permeability barrier for antibiotics.

15 ureus, but also induce tolerance to multiple antibiotics.

16 hogen that can rapidly acquire resistance to antibiotics.

17 esponded well to treatment with intravitreal antibiotics.

18 ThyX inhibitors that ultimately may serve as antibiotics.

19 terial RNA polymerase is a proven target for antibiotics.

20 which effectively enhances resistance toward antibiotics.

21 colonization resistance after treatment with antibiotics.

22 rapidly rising resistance toward beta-lactam antibiotics.

23 -positive-only compounds into broad-spectrum antibiotics.

24 rall but was 0% after initiation of systemic antibiotics.

25 nse in patients with and without exposure to antibiotics.

26 e) framework was used to classify prescribed antibiotics.

27 ntiated the activity of different classes of antibiotics.

28 mic datasets, revealing thousands of encoded antibiotics.

29 e in proton transfer during catalysis of the antibiotics.

30 mium and arsenic, as well as to biocides and antibiotics.

31 gene, confers resistance to many beta-lactam antibiotics.

32 s to avoid the immune system and last-resort antibiotics.

33 se and should be considered when prescribing antibiotics.

34 ncluding among the most clinically important antibiotics.

35 tagonistic to the bactericidal activities of antibiotics.

36 onal deficiencies, and the administration of antibiotics.

37 were subjected to breakpoint assays for ten antibiotics.

38 iod of 2 years without pre and postoperative antibiotics.

39 potential target for the development of new antibiotics.

40 nservatively with bowel rest and intravenous antibiotics.

41 All patients received standard-of-care antibiotics.

42 g with biofilm formation can thus complement antibiotics.

43 amaging agents, including many commonly used antibiotics.

44 (H(2) S) that provides some defense against antibiotics.

45 strains are resistant to a broad spectrum of antibiotics.

46 a major predictor of bacterial responses to antibiotics.

47 ndards, which consist of supportive care and antibiotics.

48 eria confers innate resistance to toxins and antibiotics.

49 efense against cytotoxic substances, such as antibiotics.

50 d death; or (3) use of long-term suppressive antibiotics.

51 and are often extensively resistant to many antibiotics.

52 e injection step to initiate AST against all antibiotics.

53 are particularly difficult to eliminate with antibiotics.

54 7 [0.30-1.54]; p = 0.35), nor fixed-duration antibiotics (1.21 [0.90-1.63]; p = 0.20) were associated

55 a full course of inpatient intravenous (IV) antibiotics, (2) received a partial course of IV antibio

56 its lipid A core is the target of polymyxin antibiotics(3,4).

57 nous fluids 57 (21%), analgesia 49 (25%) and antibiotics 40 (20%).

58 randomization; 776 were assigned to receive antibiotics (47% of whom were not hospitalized for the i

59 Of all antibiotics, 54.1% were from ambulatory care (95% CI, 52

60 withdrawal (23%), hydroxychloroquine (71%), antibiotics (74%), tocilizumab (13%), and antivirals (14

61 competition, and support the hypothesis that antibiotics act as weapons in mediating bacterial-fungal

62 Treatment of mice with antibiotics administered intranasally or subcutaneously

63 added the mandatory use of fortified topical antibiotics after cultures are obtained.

64 on oxygenation and ventilation, prophylactic antibiotics after resuscitation, postresuscitation seizu

65 One of the most commonly prescribed antibiotics against Burkholderia infections is co-trimox

66 that 20 restored the activity of beta-lactam antibiotics against carbapenem-resistant Pseudomonas aer

67 ptibility tests with one, two, or even three antibiotics against two clinically isolated multi-drug-r

68 e interval (CI) 0.253-0.657], p < 0.001) and antibiotics (aHR = 0.121 [0.0437-0.333], p < 0.0001) wer

69 oid or 5-HT receptors, or minimally absorbed antibiotics (all of which are selected according to pred

70 Nonoperative management with antibiotics alone has the potential to treat uncomplicat

71 and 60.0% in the exebacase + antibiotics and antibiotics-alone groups, respectively (difference = 10.

72 and 12.8% in the exebacase + antibiotics and antibiotics-alone groups, respectively, with a notable d

73 which is comparable with that of commercial antibiotics ampicillin and gentamicin.

74 tes multi-drug resistant (MDR) to first-line antibiotics and 60% were extensively drug-resistant (XDR

75 term premature rupture of membranes (PPROM), antibiotics and antenatal steroids are effective evidenc

76 The environmental spread of antibiotics and antibiotic resistance genes (ARGs) from

77 y 14 were 70.4% and 60.0% in the exebacase + antibiotics and antibiotics-alone groups, respectively (

78 rates were 9.7% and 12.8% in the exebacase + antibiotics and antibiotics-alone groups, respectively,

79 sary for metabolic regulation, resistance to antibiotics and antimicrobials, pathogenesis, and adhesi

80 lation to surface water, on the transport of antibiotics and ARGs in runoff and soil following land a

81 omplex procedure and includes peri-operative antibiotics and caloric restriction in addition to the a

82 ostic tools for IHRs due to 5-nitroimidazole antibiotics and can be used as supplementary to each oth

83 t 125 mg once daily while receiving systemic antibiotics and continued for 5 days postcompletion of s

84 n diseases and can confer resistance to both antibiotics and host defenses.

85 structure, enhancing biofilm eradication by antibiotics and immune cells.

86 scription; however, the risks of unwarranted antibiotics and lack of guidelines for procedures involv

87 FAS is an attractive target for antibiotics and many inhibitors are in clinical developm

88 ganic carbon (TOC) removal was achieved when antibiotics and metal oxides were allowed for preequilib

89 of the precise relationship between time-to-antibiotics and mortality for patients with possible sep

90 s, strategies such as short-term alternating antibiotics and nutrition- and microbiome-based interven

91 d assessing the relationship between time-to-antibiotics and outcomes, almost all of which are observ

92 wever, the evolutionary interactions between antibiotics and phages remain unclear, in particular, wh

93 fforts is crucial to sustain the efficacy of antibiotics and quality of infectious diseases care in c

94 Infections were treated with oral or topical antibiotics and resolved without complication, except in

95 s preassembled with custom titers of various antibiotics and splits bacterial samples upon a simple s

96 tion of potentially scarce resources such as antibiotics and supplemental oxygen.

97 model to project the effective life span of antibiotics and the number of gonorrhea cases expected u

98 rgence of superbugs developing resistance to antibiotics and the resurgence of microbial infections h

99 at to global health because of the misuse of antibiotics and the rise in drug-resistant pathogens.

100 Thus, EPs are attractive targets for novel antibiotics and their adjuvants.

101 we characterize the interaction between the antibiotics and their target, and we demonstrate that th

102 comparing patients treated immediately with antibiotics and those not treated immediately.

103 The mice received oral antibiotics and were monitored for depigmentation.

104 rge, and (3) received a partial course of IV antibiotics and were prescribed oral antibiotics on AMA

105 coverable surgical injury (30% hepatectomy), antibiotics, and a short period of starvation demonstrat

106 he first line of defense against beta-lactam antibiotics, and antibiotic stress leads to release EVs

107 nclude reduced virulence, resensitization to antibiotics, and colonization defects.

108 here is increased time spent indoors, use of antibiotics, and consumption of processed foods and decr

109 in mortality associated with each hour until antibiotics, and failure to control for large potential

110 The success of debridement, antibiotics, and implant retention (DAIR) in early perip

111 Compared with placebo or management without antibiotics, antibiotics given for 3 to 14 days were ass

112 rin transporter, bacterial thymidine kinase, antibiotics, antimicrobial peptides, bacterial antibodie

113 ; P = .006), exposure to multiple classes of antibiotics (aOR per class, 1.45; P = .02), use of opioi

114 Rifamycin antibiotics are a key component of TB therapy and a comm

115 Peptide antibiotics are an abundant and synthetically tractable

116 Few antibiotics are effective against Acinetobacter baumanni

117 into clinical practice when patients on oral antibiotics are followed up by an established OPAT servi

118 Antibiotics are highly effective in curing Mycobacterium

119 While antibiotics are likely to reduce the sensitivity of bloo

120 New structural classes of antibiotics are rare, structurally novel broad-spectrum

121 Betalactam (BL) antibiotics are the most common cause of drug hypersensi

122 Novel antibiotics are urgently needed to address the looming g

123 Novel antibiotics are urgently needed to combat multidrug-resi

124 uation dictates therapeutic decisions, where antibiotics are used for H. pylori eradication.

125 event following joint replacement surgeries; antibiotics are usually added to bone cement to prevent

126 r A(1) (A5A(1)), two cyclic lipodepsipeptide antibiotics, are reported.

127 rt the single dose of routine peri-operative antibiotics as the most influential factor of intestinal

128 mammarily with vehicle (NEG; days 4 and 10), antibiotics (ATB; days 4 and 5) or a suspension of 2.5 x

129 ll drug-tolerant borrelia we have tested two antibiotics, azlocillin and cefotaxime that were identif

130 first investigate the utility of COMBAT with antibiotics belonging to the widely used quinolone class

131 will aid in the synthesis of new beta-lactam antibiotics, beta-lactamase inhibitors, and bicyclic car

132 e., the deactivation of the most widely used antibiotics, beta-lactams (penicillins, cephalosporines,

133 al properties comparable to standard-of-care antibiotics both in vitro and in vivo, and potentiated t

134 uide to assess the bacterial load and use of antibiotics but also as a predictor for CAL loss in pati

135 biotics, (2) received a partial course of IV antibiotics but were not prescribed any antibiotics on A

136 thogens susceptible to many of these syn-BNP antibiotics, but they were also unable to develop resist

137 gy could increase the effective life span of antibiotics by 0.94 years, which is equivalent to succes

138 n, decay kinetics in the presence of various antibiotics (ciprofloxacin, cefixime, and amoxycillin),

139 growth of C. acnes with potency greater than antibiotics commonly used in the treatment of acne.

140 to ampicillin, amoxicillin, and cefotaxime, antibiotics commonly used to treat S. pyogenes infection

141 While controlling F. nucleatum through antibiotics could reduce cancer severity, this article p

142 treatment, up to 1 week after completing the antibiotics course.

143 median number of days that patients received antibiotics decreased in the teleID group (median 15, in

144 synthetic pathway may represent a target for antibiotics development to manage P. aeruginosa infectio

145 The time to empiric antibiotics did not differ significantly, but optimal an

146 gainst pathogen colonization; treatment with antibiotics disrupts the microbiota and compromises colo

147 Standard antibiotics efficiently control the symptoms.

148 Antibiotics eliminated collagenolytic E faecalis and P m

149 ting resistance to human innate immunity and antibiotics, enabling bacteria to proliferate in the hum

150 % of outbreak settings, making isolation and antibiotics essential.

151 are rare, structurally novel broad-spectrum antibiotics exceptionally so.

152 f antibiosis and of alternative functions of antibiotics exhibited at subinhibitory concentrations.

153 e model incorporating crystalloid fluids and antibiotics, exhibiting improved survival, reduced disea

154 prescribing on exposures to frequently used antibiotics experienced by potentially pathogenic bacter

155 g mode of delivery, infant feeding practice, antibiotics exposure, and other events and their impacts

156 rug-resistant (XDR), resistant to first-line antibiotics, fluoroquinolones and third generation cepha

157 female mice (n = 18) were first treated with antibiotics for 4 weeks to ablate the microbiota.

158 6 male mice were treated with broad-spectrum antibiotics for 4 weeks to deplete their gut microbiota.

159 When patients receive antibiotics for an ARI, patients may attribute their cli

160 Nine (40%) had received antibiotics for an average of 19 days (7-60) before CDI.

161 Although antibiotics for CDI exist, they are either expensive or

162 plexing clinical decision to choose multiple antibiotics for combination therapy against drug resista

163 ess of beta-lactams, which remain first-line antibiotics for many infections, is an important part of

164 therapeutic approach with new or re-purposed antibiotics for melioidosis prevention and treatment, es

165 d consent process when choosing intravitreal antibiotics for patients with specific antibiotic allerg

166 itional child deaths and reduced coverage of antibiotics for pneumonia and neonatal sepsis and of ora

167 aureus (MSSA) (19/24 [79%]) and avoidance of antibiotics for skin contaminants (30/85 [35%]).

168 antibiotics were noninferior to intravenous antibiotics for the early treatment of KLA.

169 evelopment of next-generation aminoglycoside antibiotics for the treatment of multidrug-resistant bac

170 The development of new antibiotics for these pathogens is challenging because o

171 the best balance between assuring immediate antibiotics for those patients who truly need them versu

172 These pumps are critical for extrusion of antibiotics from the cell as well as the transport of li

173 the toxicity of commonly used broad-spectrum antibiotics geneticin and puromycin to kill the non-resc

174 h placebo or management without antibiotics, antibiotics given for 3 to 14 days were associated with

175 5% CI, 1.30 to 3.98); the higher rate in the antibiotics group could be attributed to those with an a

176 Complications were more common in the antibiotics group than in the appendectomy group (8.1 vs

177 Extending therapy with oral antibiotics had superior infection-free survival for TKA

178 Rationale: The overuse of antibiotics has been an important clinical issue, and an

179 cally, the primary source of clinically used antibiotics has been microbial secondary metabolism.

180 ic resistance and declining discovery of new antibiotics has created a global health crisis.

181 Mass production and use of antibiotics has led to the rise of resistant bacteria, a

182 Direct bladder instillation of antibiotics has proved disappointing in treating UTI, li

183 Narrow-spectrum antibiotics have been found to be equivalent to extended

184 cantly reduced susceptibility to beta-lactam antibiotics have been recently described.

185 Antibiotics have many different 'mechanisms of action' t

186 void diagnostic delay and unnecessary use of antibiotics, hospitalization and surgery.

187 Antibiotics, however, are not a human invention as most

188 In a complex environment exposed to antibiotics, however, the fate of a bacterial population

189 trains that have decreased susceptibility to antibiotics; however, little is known about how these mu

190 resistance and the cross-resistance to other antibiotics (i.e., ciprofloxacin, chloramphenicol, and t

191 valent in patients who were not treated with antibiotics immediately and those who were treated on th

192 cephalosporins (1st-3rdCE) to broad-spectrum antibiotics in decreasing surgical site infections (SSI)

193 bactam are 2 of the most commonly prescribed antibiotics in hospitals.

194 increased in recent years by the wide use of antibiotics in human populations and in livestock.

195 e also unable to develop resistance to these antibiotics in laboratory experiments.

196 iation and in developing transport models of antibiotics in natural systems.

197 stimate B. bacteriovorus sensitivity against antibiotics in order to make feasible the development an

198 in 2X (PBP2X), a major target of beta-lactam antibiotics in pathogenic bacteria.

199 n these patients, and (7) role of adjunctive antibiotics in the absence of confirmed infections.

200 Bacterial resistance to antibiotics in this clinical setting further underlines

201 ts have inspired the development of numerous antibiotics in use today.

202 enem- and colistin-resistant GNB to multiple antibiotics in vitro and in vivo.

203 ie, the alternate weekly administration of 2 antibiotics) in preventing R-UTIs.

204 enzymes that confer resistance to nonrelated antibiotics, including extended-spectrum beta-lactamases

205 d as infection models for the study of novel antibiotics, including extensive investigation of novel

206 ck of action in the mitigation of release of antibiotics into the aquatic environment.

207 Resistance to macrolide antibiotics is a global concern in the treatment of Stre

208 ) Gram-negative pathogens as the pipeline of antibiotics is essentially empty.

209 MRSA resistance to beta-lactam antibiotics is mediated by two divergons that control le

210 s infections requiring prolonged intravenous antibiotics may face barriers to discharge, which could

211 However, increasing resistance to multiple antibiotics may necessitate waiting for culture-based di

212 essful reductions in consumption of targeted antibiotics may not see changes in infection rates with

213 for plasmid persistence, the application of antibiotics may promote MDR well after their original pe

214 s drainage; 71/74 (95.9%) randomized to oral antibiotics met the primary endpoint compared with 72/78

215 ic, eradicates biofilms, and synergizes with antibiotics.METHODSIn this superiority-design study, we

216 Novel antibiotics must be used sparingly to hinder the spread

217 VSG plus routine intravenous peri-operative antibiotics (n = 12), (2) VSG with intravenous vancomyci

218 ntage across beta-lactam and non beta-lactam antibiotics, non-antibiotic drugs and even diverse natur

219 ts reported a total amount of time they used antibiotics (none, <15 days, 15 days to <2 months, or >=

220 f IV antibiotics but were not prescribed any antibiotics on AMA discharge, and (3) received a partial

221 e of IV antibiotics and were prescribed oral antibiotics on AMA discharge.

222 The drug and duration-dependent effects of antibiotics on the developing neonatal gut microbiota ne

223 The impact of perinatal antibiotics on vertical transmission of microbes and ant

224 colonic motility disorders related to use of antibiotics or other factors.

225 or many patients treated with aminoglycoside antibiotics or platinum-containing chemotherapy agents.

226 defined as reduction in either the number of antibiotics or rank.

227 tinued for 5 days postcompletion of systemic antibiotics [OVP]) or no prophylaxis.

228 tly associated with the number of courses of antibiotics (P-value > 0.05), but it was significantly a

229 in the enteric neurons of mice treated with antibiotics partially restores intestinal motility.

230 nding protein poorly acylated by beta-lactam antibiotics, PBP2a.

231 Studies estimate that 30%-50% of antibiotics prescribed for hospitalized patients are ina

232 Associations between macrolide antibiotics prescribing during pregnancy and adverse chi

233 However, antibiotics promoted emergence of Candida parapsilosis,

234 en viral and but are frequently treated with antibiotics, providing a significant opportunity for ant

235 High-dose drugs, especially beta-lactam antibiotics, RCM and clindamycin, are common elicitors o

236 Antibiotics reduced bacterial load in feces and could pr

237 ges without altering susceptibility to other antibiotics, reducing growth rate, or deranging cell mor

238 attribute their clinical improvement to the antibiotics, regardless of their true benefit.

239 cal records, including clinically prescribed antibiotics, revealed the potential for antibiotic adjus

240 ry fibre, pharmacological treatments such as antibiotics (rifaximin), anti-inflammatory drugs (mesala

241 with 72/78 (92.3%) randomized to intravenous antibiotics (risk difference, 3.6%; 2-sided 95% confiden

242 The choice of antibiotics should reflect local resistance patterns and

243 Pretreatment of Fam3D(-/-) mice with antibiotics significantly reduces the severity of chemic

244 icating that double-strand breaks induced by antibiotics strongly stimulate pol IV activity.

245 uce cytotoxic drug resistance.New generation antibiotics such as biofilm inhibitors and quorum sensin

246 Treatment with antibiotics such as doxycycline or chloramphenicol is ef

247 tion has been accomplished using beta-lactam antibiotics such as the penicillins and the cephalospori

248 tions of avibactam and different beta-lactam antibiotics, suggest that it may be possible to identify

249 salinity effect on the dissipation rates of antibiotics, suggesting that common e-fate models remain

250 Early diagnosis and antibiotics targeting this emerging infectious agent can

251 escalation and exposure to broader-spectrum antibiotics than needed.

252 pper dependent inhibitors (CDIs), a class of antibiotics that are only active in the presence of copp

253 for the design of sustainable peptide-based antibiotics that can be hydrolyzed by wastewater peptida

254 anding is critical to the development of new antibiotics that disrupt cell wall biogenesis, a process

255 Aminoglycosides are a class of antibiotics that possess a less-known function to induce

256 development and testing of co-therapies with antibiotics that would increase its antimicrobial effica

257 e-site beta-lactamases hydrolyze beta-lactam antibiotics through the formation of a covalent acyl-enz

258 rically blocks binding of several classes of antibiotics to 23S rRNA, resulting in a multidrug-resist

259 beta-lactams, the most clinically successful antibiotics to date.

260 fforts on a massive scale in search of novel antibiotics to fill an urgent need for a remedy.

261 ng UTI, likely due to the failure of infused antibiotics to penetrate the bladder epithelium and accu

262 questions about which pressures compete with antibiotics to shape gonococcal evolution.

263 e residents provided data on 167 episodes of antibiotics use, of which 84 episodes that included supp

264 edge, Attitudes, and Practices (KAP) towards antibiotics' use by adults, but none of these questionna

265 he risk of AKI compared to other intravenous antibiotics used for similar indication in this cohort o

266 warming blanket use, blood transfusions and antibiotics used in the operating room, and the cost of

267 ementation on consumption of 18 ASP-targeted antibiotics using generalized linear mixed effects model

268 The increase in antibiotics was also observed among the patients' spouse

269 Delaying or withholding antibiotics was associated with increased odds of death

270 Each additional day of antibiotics was associated with lower richness of anaero

271 tinuation of therapy, each additional day of antibiotics was associated with lower richness of obliga

272 No significant difference between antibiotics was demonstrated for clinical failure, micro

273 Same-day injection of intravitreal antibiotics was the universal first-line therapy.

274 Our findings suggest that moderate doses of antibiotics, well below the MIC of resistant strains, ma

275 Empirical intravenous antibiotics were administered in 21.1% of low-risk episo

276 Inpatient antibiotics were administered to 2020 (94%) patients dur

277 study, we found that immunosuppressants and antibiotics were associated with decreased risk of ADA d

278 Antibiotics were detected in 39% (1145/2939) of urine sa

279 Risk quotients for test antibiotics were generated to quantify risk.

280 f antibiotics were prescribed optimally (ie, antibiotics were indicated, and a guideline-concordant a

281 Oral antibiotics were noninferior to intravenous antibiotics

282 /136), 36.6% (66/180), and 34.9% (67/192) of antibiotics were prescribed optimally (ie, antibiotics w

283 response criteria were not met, further oral antibiotics were prescribed until clinical response was

284 herichia coli and Klebsiella pneumoniae once antibiotics were removed.

285 cs did not differ significantly, but optimal antibiotics were started earlier after introduction of t

286 14,138 (36%), escalation in 5,129 (13%), and antibiotics were unchanged in 19,959 (51%).

287 cin and fortified tobramycin, although other antibiotics were used during treatment if warranted.

288 drive whether patients seek care or request antibiotics when they have subsequent ARIs.

289 gn selection agents serve as alternatives to antibiotics, which are costly and risk spread of antibio

290 xperimental animals, except for radiolabeled antibiotics, which have been examined in humans without

291 iverse functions, including siderophores and antibiotics, which often require export to the extracell

292 cally mixed for 10 min with serially diluted antibiotics with a novel, membrane-type micromixer consi

293 sis is suspected, broad-spectrum intravenous antibiotics with ability to penetrate pancreatic necrosi

294 Practitioners are more likely to prescribe antibiotics with bone grafting and as complexity of the

295 acterial evaluation of group A streptogramin antibiotics with extensive structural variability.

296 urgent need for novel bacterial targets and antibiotics with novel modes of action.

297 from patients with very long intervals until antibiotics with patients with shorter intervals and rep

298 ess to reward manufacturers of certain novel antibiotics with transferrable market exclusivity vouche

299 less likely to fail the goal of beta-lactam antibiotics within 1 hour (44.6% vs 57.3%; odds ratio, 2

300 MSM population each year with the first-line antibiotics without worsening the burden of gonorrhea.